Current live-attenuated dengue vaccines require strict cold chain storage. Methods to preserve dengue virus (DENV) viability, which enable vaccines to be transported and administered at ambient temperatures, will be decisive towards the implementation of affordable global vaccina- Dengue virus can be stabilized using saccharide-based formulations and coated on microneedle array vaccine patches for storage in dry state with preserved viability at ambient temperature (VSMN; virus-stabilized microneedle arrays).
| INTRODUCTION
There are two main criteria that denote a successful vaccine-it must elicit life-long protective immunity against disease from wild-type microbial infection and it must be accessible by those who live in pathogen endemic areas. Lessening the dependence on cold chain infrastructure reduces vaccine cost and improves the capacity to distribute doses to geographically remote communities. [1] [2] [3] The controlled temperature chain (CTC) involves final sections of vaccine transport at ambient temperature through infrastructure-weak areas and has the potential to reduce vaccination cost by up to 50%. This cold chain is especially critical for enveloped viruses, such as flaviviruses, that are more unstable than nonenveloped viruses such as poliovirus.
Our efforts are directed towards the development of a vaccine against dengue virus (DENV). DENV infection is the leading cause of mosquito-borne illness throughout the tropical world, where an estimated 2.5 billion people live at risk of infection each year. 5, 6 Travelers to dengue endemic countries are also at risk of disease and facilitating viral transmission. 6, 7 Since the isolation of DENV in 1943, the development of an effective vaccine that provides balanced, long-lasting immunity has been challenging. This is partly due to the complexity of dengue epidemiology, population immunity, and the interplay between viral pathogenesis and host immunological mechanisms. [8] [9] [10] [11] [12] Like other successful flavivirus vaccines against yellow fever and Japanese encephalitis, the majority of dengue vaccine candidates either approved for limited license or in Phase III trials are LAVs. 8, [13] [14] [15] These require shipment in lyophilized form at 4 C and must be reconstituted immediately before use to avoid loss in potency. 16, 17 Therefore, systems enabling the preservation of DENV viability in dry formulation and at ambient temperatures will be essential for the development of LAVs that can be delivered and administered under CTC conditions.
Flaviviruses, such as DENV, are transmitted by mosquitos following skin penetration by the mosquito fascicle, nature's ideal polymeric microneedle (MN) composed of chitin. The virus infects and replicates within dermal dendritic cells and Langerhans cells, which traffic to lymph nodes and are responsible for processing and presentation of viral antigens during the induction of antiviral immune responses. 18, 19 Intradermal delivery of dengue LAVs would leverage this immune activation in the skin. Hence, another attractive approach for dengue vaccination involves the use of minimally invasive MN-based skin patches. MNs have been successfully used to deliver a broad range of small molecule drugs, biotherapeutics and vaccines to the skin and mucosal surfaces. 20 By mimicking the immunological context of natural dengue infection through the skin, native pathways are activated to elicit robust protective immunity. [21] [22] [23] Furthermore, MN-based therapeutics offer additional logistical benefits including low cost of materials, and easy pain-free administration, which lessens the dependence on trained medical staff and offers the potential for improved compliance. 20, 24, 25 We aimed to develop a dengue LAV vaccine platform that combined the advantages of intradermal delivery using MNs with a tailored stabilizing formulation optimized to preserve virus viability. Here we describe the fabrication and efficacy of dengue virus-stabilized microneedle arrays (VSMNs) formulated to enable virus vaccine storage in the dry state at ambient temperature. VSMNs applied to the skin were shown to induce protective immunity comparable to that of freshly prepared liquid virus. These steps represent important advances towards the development of intradermal dengue vaccines designed for the CTC supply chain. 
| RESULTS AND DISCUSSION

| VSMN-mediated immunity protects from viral challenge
An effective vaccine must provide protection from disease challenge.
To demonstrate the quality of immunity generated by VSMN, we (Figure 5b ). This confirms that immunization with stabilized live-attenuated DENV delivered from our VSMN platform can achieve strong protective immunity that is noninferior to subcutaneous vaccination using fresh virus.
| Towards long-term ambient temperature storage
VSMNs provide the capacity for ambient temperature storage of dry formulated virus. In experiments conducted to validate VSMN- 
| Conclusions
The stability of virus particles to retain infectivity is critical for LAV efficacy and the protection of immunized patients. Stabilizing 
| Confocal microscopy
Microscopy was performed using a Zeiss Axio Observer Z1 LSM 700 (488 nm laser) at 10× objective. Normalized signal intensities were determined by integrating the total confocal fluorescence signal from z-stacks collected through the length of individual MNs and normalizing to the total fluorescence of MNs prior to skin application.
Image processing and data analysis was performed using Image J. BHK-21 cell monolayers were infected with 200 μL incubated virus for 1 hr at 37 C. Cells were overlaid with RPMI/2% CMC/1% pen/strep, incubated for 5 days, then plaques were stained and counted as described for the plaque assay. The serum dilution resulting in 50% inhibition of plaque formation relative to virus only control (PRNT 50 ) was determined in Prism using a nonlinear regression with variable slope (4 parameters) constrained to 100 and 0 for top and bottom, respectively. 
| Plaque assay
| Viral challenge
| Statistical analysis
Data sets were analyzed using t tests, Mann-Whitney tests or KruskalWallis tests using Prism (GraphPad Software, San Diego, CA). Unless otherwise indicated, data is presented as mean ± SEM. with statistical significance defined by p-values; *p < 0.05, **p < 0.01, ***p < 0.001.
